Navigation Links
Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
Date:8/10/2011

LOS ANGELES, Aug. 10, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).  Under the terms of the five-year cooperative research and development agreement, Genesis Biopharma will work with Steven A. Rosenberg, M.D., Ph.D., the NCI Surgery Branch Chief, to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's tumor infiltrating lymphocytes.

Specifically, the CRADA will (i) support the in vitro development of improved methods for the generation and selection of tumor infiltrating lymphocytes with anti-tumor reactivity from patients with metastatic melanoma, (ii) develop approaches for large-scale production of tumor infiltrating lymphocytes that are in accord with Good Manufacturing Practice (GMP) procedures suitable for use in treating patients with metastatic melanoma, and (iii) allow the conduct of clinical trials using these improved methods of generating tumor infiltrating lymphocytes as well as improved adoptive cell therapy preparative regimens for the treatment of metastatic melanoma.

Both Genesis Biopharma and the NCI may provide personnel, services, facilities, equipment or other resources under the agreement.  Genesis Biopharma will provide funding for the CRADA research project.  Genesis Biopharma will have an exclusive option to negotiate an exclusive license to any new inventions developed jointly or solely by NCI scientists as a result of the research activities under the CRADA.

"The medical oncology community is very aware of Dr. Rosenberg's groundbreaking work using adoptive cell therapy and tumor infiltrating lymphocytes for the treatment of metastatic melanoma," stated Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma.
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
2. Genesis Biopharma Names David Voyticky to Board of Directors
3. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
4. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
5. Genesis Biopharma Conference Call and Webcast Reminder
6. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
7. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
8. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
9. ThermoGenesis Announces China Customer Implements Cord Blood Products
10. Tissue Genesis Begins FDA-Approved Clinical Trial
11. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Men’s skin is ... La-roche Posay ) and has been known to react ... some men may be far from puberty, other acne causing ... pores, causing breakouts, and threatening skin with unsightly acne scars. ... from Men’s Health on how to reduce and ...
(Date:5/17/2013)... CA (PRWEB) May 17, 2013 IAC Industries ... Technologies, a start up laboratory needing to set up and ... moving to a larger facility within a year’s time. How ... knowledge that the laboratory is temporary? What is efficient and ... Series modular workstations from IAC Industries. The planners at DisperSol ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... GBS and EV Expand GeneXpert(R) Test Menu in ... Cepheid (Nasdaq:,CPHD) today announced that Health Canada ... the rapid detection of Group B Streptococcus (GBS),and ... EV-associated,meningitis. These tests join Xpert MRSA, which received ...
... 3 American Oriental,Bioengineering (NYSE: AOB ) ... private,offer, subject to market conditions and other factors, ... of newly,issued convertible preferred stock. The convertible preferred ... arrears, and will be,convertible upon the occurrence of ...
... 3, 2008, TIME: 9:30 ... Dr. Candace Kendle, Chairman and CEO Kendle (Nasdaq: KNDL ... June 3 at 9:30 a.m. Eastern Time to,discuss the acquisition of ... provide an update on second quarter,progress. A question and answer session ...
Cached Biology Technology:Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 3Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 4American Oriental Bioengineering Announces Proposed Private Offering to Raise $125 Million via Convertible Preferred Stock 2Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress 2
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The AGA Research ... Augustyn and Damian Augustyn Award in Digestive Cancer, which ... School of Medicine at the University of Pennsylvania, Philadelphia, ... Zeb1 in pancreas development, regeneration and cancer progression. , ... award in honor of two distinguished clinicians and AGA ...
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... and Sustainable Global Logistics Operations) is aiming to cut ... of intermodal loading systems and the boosting of intelligent ... organisations with experience in the logistics sector and in ... and a duration of three and a half years. ... semantic components and ontologies shared by the users, objects ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... , PARIS , Feb. 4 ... Eurofins Scientific, a global leader in bio-analysis. , Under a ... connect 16 key Eurofins laboratories and research centers in ... company,s global customer base.  Verizon will use MPLS (multi-protocol label ...
... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
... College of Georgia researchers are seeking to refine cancer ... Chinese medicine. Celastrol, derived from trees and shrubs ... to treat symptoms such as fever, chills, joint pain ... play a role in cancer treatment by inactivating a ...
Cached Biology News:Verizon Business to Provide Global IP for Eurofins Scientific 2Verizon Business to Provide Global IP for Eurofins Scientific 3Scientists find quantum mechanics at work in photosynthesis 2Plant derivative could help refine cancer treatment 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Biology Products: